|Bid||4.30 x 400|
|Ask||4.80 x 100|
|Day's Range||4.62 - 4.79|
|52 Week Range||4.20 - 9.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.83|
PLYMOUTH MEETING, Pa., Nov. 10, 2017-- Inovio Pharmaceuticals, Inc. today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112, ...
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.
The top and bottom lines aren't that critical for Inovio right now. It's all about the pipeline -- and the biotech's cash position.
PLYMOUTH MEETING, Pa., Nov. 09, 2017-- Inovio Pharmaceuticals, Inc. today announced that the Company will participate in the following upcoming investment conferences:. Stifel 2017 Healthcare Conference ...
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 40 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
PLYMOUTH MEETING, Pa., Nov. 08, 2017-- Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2017.. Total revenue was $2.6 million for the three months ended ...
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.
Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.
PLYMOUTH MEETING, Pa., Nov. 01, 2017-- Inovio Pharmaceuticals, Inc. today initiated a phase 1 b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma designed to evaluate cemiplimab, a ...
PLYMOUTH MEETING, Pa., Oct. 26, 2017-- Inovio Pharmaceuticals, Inc. announced today that it will host a conference call and live webcast to report its 2017 third quarter financial results on Wednesday, ...
Inovio Pharmaceuticals Inc. announced positive results from a study that showed its experimental DNA vaccine, being developed in a partnership with the U.S. Army, provided 100 percent protection for non-human primates given a lethal dose of the Lassa fever virus. The Lassa virus is a virulent hemorrhagic virus similar to Ebola that annually infects up to 300,000 people, mostly in Central and West Africa regions, and is responsible for about 5,000 deaths a year. Inovio’s study was funded by a previously awarded $3.5 million grant from the National Institute of Allergy and Infectious Diseases.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Inovio Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
PLYMOUTH MEETING, Pa., Oct. 24, 2017-- Inovio Pharmaceuticals, Inc. today announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose ...
Inovio Pharmaceuticals Inc (NASDAQ:INO), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGS over the last few months. AsRead More...
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Inovio Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to INO-US. Comparing the performance and risk of Inovio Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), following which ...
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Below is a list of notable corporate events for the week beginning October 16. Note, this list is not comprehensive and all dates are subject to change. Monday Earnings Netflix, Inc (NASDAQ: NFLX ) Q3 ...